About Authors:
Najneen S. Shaikh1*, Mr. MAYURESH. K. RAUT2
1Sinhgad Institute of Pharmaceutical Sciences (SIPS), Lonavala
2Asst. Professor Of Phamaceutical Chemistry
Sinhgad Technical Education Society,
Kusgaon (Bk), Lonavala- 410401
*naj.pharma.23@gmail.com
ABTRACT
Glycogen synthase kinase 3 (GSK-3) is a serine/threonine protein kinase, that mediates the addition of phosphate molecules on certain serine and threonine amino acids in particular cellular substrates.
Glycogen synthase kinase-3 (GSK3) has recently been linked to mood disorders and schizophrenia, and the neurotransmitter systems and therapeutic treatments associated with these diseases. GSK3 is a widely influential enzyme that is capable of phosphorylating, and thereby regulating, over forty known substrates. Four mechanisms regulating GSK3 (phosphorylation, protein complexes, localization, and substrate phosphorylation) combine to provide substrate-specific regulation of the actions of GSK3. Several intracellular signaling cascades converge on GSK3 to modulate its activity, and several neurotransmitter systems also regulate GSK3, including serotonergic, dopaminergic, cholinergic, and glutamatergic systems. Because of changes in these neurotransmitter systems and the actions of therapeutic drugs, GSK3 has been linked to the mood disorders, bipolar disorder and depression, and to schizophrenia.
(adsbygoogle = window.adsbygoogle || []).push({});